Radiopharmaceuticals (Nuclear Medicine) Market, 2012 to 2023
Global Radiopharmaceuticals (Nuclear Medicine) Market: By Product Type (Diagnostic Radiopharmaceuticals (SPECT Radiopharmaceuticals and PET Radiopharmaceuticals) and Therapeutic Radiopharmaceuticals (Beta Emitters, Alpha emitters, Brachytherapy, and Others)), By Application (Oncology, Neurological disorders, Cardiovascular diseases, Thyroid, and Others), By Route of Administration (Oral, Inhalation, and Parenteral) By End User (Hospitals, Clinics, Diagnostic Centers, and Research Institutes), and Geography (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023
Global Radiopharmaceuticals (Nuclear Medicine) Market Outline:
Global radiopharmaceuticals (nuclear medicine) market report gives a comprehensive outlook on radiopharmaceuticals across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). The report on radiopharmaceuticals/nuclear medicine market gives historical, current, and future market sizes (US$ Mn) on the basis of product type, application area, route of administration, end user, and geographic regions. This report studies Global radiopharmaceuticals (nuclear medicine) market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, radiopharmaceuticals/nuclear medicine market report includes new product introductions; regulatory scenario and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed radiopharmaceuticals market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the Global radiopharmaceuticals (nuclear medicine) market report include suppliers, manufacturers, marketers, policymakers, and healthcare service providers engaged in manufacturing, supply and prescribing of radiopharmaceuticals.
Radiopharmaceuticals (Nuclear Medicine) Market:
Global radiopharmaceuticals (nuclear medicine) market estimated to be valued US$ 5,146 Mn in 2017 and poised to grow at CAGR of 8.9% over 2017-2023. The market for radiopharmaceuticals projected to reach US$ 8,564 Mn by 2023 owing to increasing adoption of radiotherapeutic and diagnostic procedures across the globe.
Growing prevalence of cancer and cardiovascular diseases expected to drive adoption of radiopharmaceuticals across the globe
The global radiopharmaceuticals (nuclear medicine) market is growing at a significant CAGR due to rising in the prevalence of various types of cancers and cardiovascular diseases. The growing prevalence of various cancers resulted in an increased adoption of radiopharmaceuticals in diagnosis and treatment of several cancers in developed economies. For instance, according to globocan cancer statistics, There were 14.1 million new cancer cases, 8.2 million cancer deaths and 32.6 million people living with cancer (within 5 years of diagnosis) in 2012 worldwide. Moreover, advances in technology such as introduction of PET radiotracers and targeted radioimmunotherapies expected to drive the overall market revenue growth over the forecast period
Emergence of radiopharmaceuticals (nuclear medicine) as safer alternative to the conventional diagnosis
The development of effective radiopharmaceuticals for diagnosis and treatment expected to drive the market revenue growth over the forecast period. The advances in imaging devices with radio-activity are aiding healthcare professionals in effective diagnosis. Moreover, radio-imaging diagnosis is considered as an effective alternative to the conventional diagnosis techniques such as X-rays which expected to boost the market demand for diagnostic radiopharmaceuticals across the globe. In addition, increase in the healthcare expenditure, radiopharmaceuticals abundance, and non-invasiveness in the treatment and diagnostic procedure might bolster the nuclear medicine market over the forecast period.
North America accounts for larger revenue share in global radiopharmaceuticals (nuclear medicine) market
North America market holds the higher revenue share in global radiopharmaceuticals (nuclear medicine) market and projected to remain same over the forecast period owing to rising FDA approvals and production of radiopharmaceuticals in the region. Asia Pacific radiopharmaceuticals (nuclear medicine) market projected to grow at significant CAGR over the forecast period in comparison with other regions owing to conducive business environment and rising PET installations in the region
Competition Assessment
Key players profiled in the global radiopharmaceuticals (nuclear medicine) market include:
Advanced Accelerator Applications S.A. (France)
Bayer AG (Germany)
Bracco Imaging S.p.A (Italy)
Cardinal Health, Inc. (U.S.)
Eli Lilly and Co. (U.S.)
GE Healthcare (U.S.)
IBA Molecular Imaging (Belgium)
Jubilant Life Sciences Ltd (India)
Lantheus Medical Imaging, Inc. (U.S.)
Mallinckrodt plc (Ireland)
Navidea Biopharmaceutical (U.S.)
Nordion, Inc. (Canada)
Siemens Healthineers (Germany)
Players in the radiopharmaceuticals (nuclear medicine) market are focusing on expanding product portfolio, acquisitions to garner larger market revenue share in global radiopharmaceuticals (nuclear medicine) market
Global Radiopharmaceuticals (Nuclear Medicine) Market Outline:
Global radiopharmaceuticals (nuclear medicine) market report gives a comprehensive outlook on radiopharmaceuticals across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). The report on radiopharmaceuticals/nuclear medicine market gives historical, current, and future market sizes (US$ Mn) on the basis of product type, application area, route of administration, end user, and geographic regions. This report studies Global radiopharmaceuticals (nuclear medicine) market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, radiopharmaceuticals/nuclear medicine market report includes new product introductions; regulatory scenario and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed radiopharmaceuticals market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the Global radiopharmaceuticals (nuclear medicine) market report include suppliers, manufacturers, marketers, policymakers, and healthcare service providers engaged in manufacturing, supply and prescribing of radiopharmaceuticals.
Radiopharmaceuticals (Nuclear Medicine) Market:
Global radiopharmaceuticals (nuclear medicine) market estimated to be valued US$ 5,146 Mn in 2017 and poised to grow at CAGR of 8.9% over 2017-2023. The market for radiopharmaceuticals projected to reach US$ 8,564 Mn by 2023 owing to increasing adoption of radiotherapeutic and diagnostic procedures across the globe.
Growing prevalence of cancer and cardiovascular diseases expected to drive adoption of radiopharmaceuticals across the globe
The global radiopharmaceuticals (nuclear medicine) market is growing at a significant CAGR due to rising in the prevalence of various types of cancers and cardiovascular diseases. The growing prevalence of various cancers resulted in an increased adoption of radiopharmaceuticals in diagnosis and treatment of several cancers in developed economies. For instance, according to globocan cancer statistics, There were 14.1 million new cancer cases, 8.2 million cancer deaths and 32.6 million people living with cancer (within 5 years of diagnosis) in 2012 worldwide. Moreover, advances in technology such as introduction of PET radiotracers and targeted radioimmunotherapies expected to drive the overall market revenue growth over the forecast period
Emergence of radiopharmaceuticals (nuclear medicine) as safer alternative to the conventional diagnosis
The development of effective radiopharmaceuticals for diagnosis and treatment expected to drive the market revenue growth over the forecast period. The advances in imaging devices with radio-activity are aiding healthcare professionals in effective diagnosis. Moreover, radio-imaging diagnosis is considered as an effective alternative to the conventional diagnosis techniques such as X-rays which expected to boost the market demand for diagnostic radiopharmaceuticals across the globe. In addition, increase in the healthcare expenditure, radiopharmaceuticals abundance, and non-invasiveness in the treatment and diagnostic procedure might bolster the nuclear medicine market over the forecast period.
North America accounts for larger revenue share in global radiopharmaceuticals (nuclear medicine) market
North America market holds the higher revenue share in global radiopharmaceuticals (nuclear medicine) market and projected to remain same over the forecast period owing to rising FDA approvals and production of radiopharmaceuticals in the region. Asia Pacific radiopharmaceuticals (nuclear medicine) market projected to grow at significant CAGR over the forecast period in comparison with other regions owing to conducive business environment and rising PET installations in the region
Competition Assessment
Key players profiled in the global radiopharmaceuticals (nuclear medicine) market include:
Advanced Accelerator Applications S.A. (France)
Bayer AG (Germany)
Bracco Imaging S.p.A (Italy)
Cardinal Health, Inc. (U.S.)
Eli Lilly and Co. (U.S.)
GE Healthcare (U.S.)
IBA Molecular Imaging (Belgium)
Jubilant Life Sciences Ltd (India)
Lantheus Medical Imaging, Inc. (U.S.)
Mallinckrodt plc (Ireland)
Navidea Biopharmaceutical (U.S.)
Nordion, Inc. (Canada)
Siemens Healthineers (Germany)
Players in the radiopharmaceuticals (nuclear medicine) market are focusing on expanding product portfolio, acquisitions to garner larger market revenue share in global radiopharmaceuticals (nuclear medicine) market
1. EXECUTIVE SUMMARY
2. GLOBAL RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET INTRODUCTION
2.1. Global Radiopharmaceuticals (Nuclear Medicine) Market – Taxonomy
2.2. Global Radiopharmaceuticals (Nuclear Medicine) Market –Definitions
2.2.1. Product Type
2.2.2. Application
2.2.3. Route of Administration
2.2.4. End-User
3. GLOBAL RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Radiopharmaceuticals (Nuclear Medicine) Market Dynamics – Factors Impact Analysis
3.6. Global Radiopharmaceuticals (Nuclear Medicine) Market – Regulations
3.6.1. U.S.
3.6.2. Europe
4. GLOBAL RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET, BY PRODUCT TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Diagnostic Radiopharmaceuticals
5.1.1. SPECT Radiopharmaceuticals
5.1.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.1.3. Market Opportunity Analysis
5.1.2. PET Radiopharmaceuticals
5.1.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.2.3. Market Opportunity Analysis
5.2. Therapeutic Radiopharmaceuticals
5.2.1. Beta Emitters
5.2.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.1.3. Market Opportunity Analysis
5.2.2. Alpha emitters
5.2.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.2.3. Market Opportunity Analysis
5.2.3. Brachytherapy
5.2.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3.3. Market Opportunity Analysis
5.2.4. Others
5.2.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.4.3. Market Opportunity Analysis
6. GLOBAL RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET FORECAST, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Oncology
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Neurological disorders
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Cardiovascular diseases
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Thyroid
6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Others
6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
7. GLOBAL RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET FORECAST, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Oral
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Inhalation
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Parenteral
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. GLOBAL RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET FORECAST, BY END-USER, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. Hospitals
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Clinics
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Diagnostic Centers
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Research Institutes
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
9. GLOBAL RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1. North America
9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.5.3. Market Opportunity Analysis
9.6. Global Radiopharmaceuticals (Nuclear Medicine) Market - Opportunity Analysis Index, By Product Type, By Application, By Route of Administration, By End-User, and Region, 2017 – 2023
10. NORTH AMERICA RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Diagnostic Radiopharmaceuticals
10.1.1.1. SPECT Radiopharmaceuticals
10.1.1.2. PET Radiopharmaceuticals
10.1.2. Therapeutic Radiopharmaceuticals
10.1.2.1. Beta Emitters
10.1.2.2. Alpha emitters
10.1.2.3. Brachytherapy
10.1.2.4. Others
10.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Oncology
10.2.2. Neurological disorders
10.2.3. Cardiovascular diseases
10.2.4. Thyroid
10.2.5. Others
10.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Oral
10.3.2. Inhalation
10.3.3. Parenteral
10.4. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.4.1. Hospitals
10.4.2. Clinics
10.4.3. Diagnostic Centers
10.4.4. Research Institutes
10.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.5.1. U.S.
10.5.2. Canada
10.6. North America Radiopharmaceuticals (Nuclear Medicine) Market - Opportunity Analysis Index, By Product Type, By Application, By Route of Administration, By End-User, and Country, 2017 – 2023
10.7. North America Radiopharmaceuticals (Nuclear Medicine) Market Dynamics – Trends
11. EUROPE RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Diagnostic Radiopharmaceuticals
11.1.1.1. SPECT Radiopharmaceuticals
11.1.1.2. PET Radiopharmaceuticals
11.1.2. Therapeutic Radiopharmaceuticals
11.1.2.1. Beta Emitters
11.1.2.2. Alpha emitters
11.1.2.3. Brachytherapy
11.1.2.4. Others
11.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Oncology
11.2.2. Neurological disorders
11.2.3. Cardiovascular diseases
11.2.4. Thyroid
11.2.5. Others
11.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Oral
11.3.2. Inhalation
11.3.3. Parenteral
11.4. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.4.1. Hospitals
11.4.2. Clinics
11.4.3. Diagnostic Centers
11.4.4. Research Institutes
11.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.5.1. Germany
11.5.2. UK
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Russia
11.5.7. Poland
11.5.8. Rest of Europe
11.6. Europe Radiopharmaceuticals (Nuclear Medicine) Market - Opportunity Analysis Index, By Product Type, By Application, By Route of Administration, By End-User,and Country, 2017 – 2023
11.7. Europe Radiopharmaceuticals (Nuclear Medicine) Market Dynamics – Trends
12. ASIA-PACIFIC RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Diagnostic Radiopharmaceuticals
12.1.1.1. SPECT Radiopharmaceuticals
12.1.1.2. PET Radiopharmaceuticals
12.1.2. Therapeutic Radiopharmaceuticals
12.1.2.1. Beta Emitters
12.1.2.2. Alpha emitters
12.1.2.3. Brachytherapy
12.1.2.4. Others
12.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Oncology
12.2.2. Neurological disorders
12.2.3. Cardiovascular diseases
12.2.4. Thyroid
12.2.5. Others
12.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Oral
12.3.2. Inhalation
12.3.3. Parenteral
12.4. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Hospitals
12.4.2. Clinics
12.4.3. Diagnostic Centers
12.4.4. Research Institutes
12.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. ASEAN
12.5.5. Australia & New Zealand
12.5.6. Rest of Asia-Pacific
12.6. Asia-Pacific Radiopharmaceuticals (Nuclear Medicine) Market - Opportunity Analysis Index, By Product Type, By Application, By Route of Administration, By End-User,and Country, 2017 – 2023
12.7. Europe Radiopharmaceuticals (Nuclear Medicine) Market Dynamics – Trends
13. LATIN AMERICA RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Diagnostic Radiopharmaceuticals
13.1.1.1. SPECT Radiopharmaceuticals
13.1.1.2. PET Radiopharmaceuticals
13.1.2. Therapeutic Radiopharmaceuticals
13.1.2.1. Beta Emitters
13.1.2.2. Alpha emitters
13.1.2.3. Brachytherapy
13.1.2.4. Others
13.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Oncology
13.2.2. Neurological disorders
13.2.3. Cardiovascular diseases
13.2.4. Thyroid
13.2.5. Others
13.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Oral
13.3.2. Inhalation
13.3.3. Parenteral
13.4. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.4.1. Hospitals
13.4.2. Clinics
13.4.3. Diagnostic Centers
13.4.4. Research Institutes
13.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Argentina
13.5.4. Venezuela
13.5.5. Rest of Latin America
13.6. Latin America Radiopharmaceuticals (Nuclear Medicine) Market - Opportunity Analysis Index, By Product Type, By Application, By Route of Administration, By End-User, and Country, 2017 – 2023
13.7. Latin America Radiopharmaceuticals (Nuclear Medicine) Market Dynamics – Trends
14. MIDDLE EAST AND AFRICA RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
14.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.1. Diagnostic Radiopharmaceuticals
14.1.1.1. SPECT Radiopharmaceuticals
14.1.1.2. PET Radiopharmaceuticals
14.1.2. Therapeutic Radiopharmaceuticals
14.1.2.1. Beta Emitters
14.1.2.2. Alpha emitters
14.1.2.3. Brachytherapy
14.1.2.4. Others
14.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.2.1. Oncology
14.2.2. Neurological disorders
14.2.3. Cardiovascular diseases
14.2.4. Thyroid
14.2.5. Others
14.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.3.1. Oral
14.3.2. Inhalation
14.3.3. Parenteral
14.4. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.4.1. Hospitals
14.4.2. Clinics
14.4.3. Diagnostic Centers
14.4.4. Research Institutes
14.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.5.1. Gulf Cooperation Council (GCC) Countries
14.5.2. Israel
14.5.3. South Africa
14.5.4. Rest of MEA
14.6. MEA Radiopharmaceuticals (Nuclear Medicine) Market - Opportunity Analysis Index, By Product Type, By Application, By Route of Administration, By End-User, and Country, 2017 – 2023
14.7. MEA Radiopharmaceuticals (Nuclear Medicine) Market Dynamics – Trends
15. COMPETITION LANDSCAPE
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Disease Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
15.2.1. Advanced Accelerator Applications S.A. (France)
15.2.2. Bayer AG (Germany)
15.2.3. Bracco Imaging S.p.A (Italy)
15.2.4. Cardinal Health, Inc. (U.S.)
15.2.5. Eli Lilly and Co. (U.S.)
15.2.6. GE Healthcare (U.S.)
15.2.7. IBA Molecular Imaging (Belgium)
15.2.8. Jubilant Life Sciences Ltd (India)
15.2.9. Lantheus Medical Imaging, Inc. (U.S.)
15.2.10. Mallinckrodt plc (Ireland)
15.2.11. Navidea Biopharmaceutical (U.S.)
15.2.12. Nordion, Inc. (Canada)
15.2.13. Siemens Healthineers (Germany)
16. RESEARCH METHODOLOGY
17. KEY ASSUMPTIONS AND ACRONYMS
2. GLOBAL RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET INTRODUCTION
2.1. Global Radiopharmaceuticals (Nuclear Medicine) Market – Taxonomy
2.2. Global Radiopharmaceuticals (Nuclear Medicine) Market –Definitions
2.2.1. Product Type
2.2.2. Application
2.2.3. Route of Administration
2.2.4. End-User
3. GLOBAL RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Radiopharmaceuticals (Nuclear Medicine) Market Dynamics – Factors Impact Analysis
3.6. Global Radiopharmaceuticals (Nuclear Medicine) Market – Regulations
3.6.1. U.S.
3.6.2. Europe
4. GLOBAL RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET, BY PRODUCT TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Diagnostic Radiopharmaceuticals
5.1.1. SPECT Radiopharmaceuticals
5.1.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.1.3. Market Opportunity Analysis
5.1.2. PET Radiopharmaceuticals
5.1.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.2.3. Market Opportunity Analysis
5.2. Therapeutic Radiopharmaceuticals
5.2.1. Beta Emitters
5.2.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.1.3. Market Opportunity Analysis
5.2.2. Alpha emitters
5.2.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.2.3. Market Opportunity Analysis
5.2.3. Brachytherapy
5.2.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3.3. Market Opportunity Analysis
5.2.4. Others
5.2.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.4.3. Market Opportunity Analysis
6. GLOBAL RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET FORECAST, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Oncology
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Neurological disorders
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Cardiovascular diseases
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Thyroid
6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Others
6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
7. GLOBAL RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET FORECAST, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Oral
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Inhalation
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Parenteral
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. GLOBAL RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET FORECAST, BY END-USER, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. Hospitals
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Clinics
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Diagnostic Centers
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Research Institutes
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
9. GLOBAL RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1. North America
9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.5.3. Market Opportunity Analysis
9.6. Global Radiopharmaceuticals (Nuclear Medicine) Market - Opportunity Analysis Index, By Product Type, By Application, By Route of Administration, By End-User, and Region, 2017 – 2023
10. NORTH AMERICA RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Diagnostic Radiopharmaceuticals
10.1.1.1. SPECT Radiopharmaceuticals
10.1.1.2. PET Radiopharmaceuticals
10.1.2. Therapeutic Radiopharmaceuticals
10.1.2.1. Beta Emitters
10.1.2.2. Alpha emitters
10.1.2.3. Brachytherapy
10.1.2.4. Others
10.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Oncology
10.2.2. Neurological disorders
10.2.3. Cardiovascular diseases
10.2.4. Thyroid
10.2.5. Others
10.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Oral
10.3.2. Inhalation
10.3.3. Parenteral
10.4. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.4.1. Hospitals
10.4.2. Clinics
10.4.3. Diagnostic Centers
10.4.4. Research Institutes
10.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.5.1. U.S.
10.5.2. Canada
10.6. North America Radiopharmaceuticals (Nuclear Medicine) Market - Opportunity Analysis Index, By Product Type, By Application, By Route of Administration, By End-User, and Country, 2017 – 2023
10.7. North America Radiopharmaceuticals (Nuclear Medicine) Market Dynamics – Trends
11. EUROPE RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Diagnostic Radiopharmaceuticals
11.1.1.1. SPECT Radiopharmaceuticals
11.1.1.2. PET Radiopharmaceuticals
11.1.2. Therapeutic Radiopharmaceuticals
11.1.2.1. Beta Emitters
11.1.2.2. Alpha emitters
11.1.2.3. Brachytherapy
11.1.2.4. Others
11.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Oncology
11.2.2. Neurological disorders
11.2.3. Cardiovascular diseases
11.2.4. Thyroid
11.2.5. Others
11.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Oral
11.3.2. Inhalation
11.3.3. Parenteral
11.4. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.4.1. Hospitals
11.4.2. Clinics
11.4.3. Diagnostic Centers
11.4.4. Research Institutes
11.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.5.1. Germany
11.5.2. UK
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Russia
11.5.7. Poland
11.5.8. Rest of Europe
11.6. Europe Radiopharmaceuticals (Nuclear Medicine) Market - Opportunity Analysis Index, By Product Type, By Application, By Route of Administration, By End-User,and Country, 2017 – 2023
11.7. Europe Radiopharmaceuticals (Nuclear Medicine) Market Dynamics – Trends
12. ASIA-PACIFIC RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Diagnostic Radiopharmaceuticals
12.1.1.1. SPECT Radiopharmaceuticals
12.1.1.2. PET Radiopharmaceuticals
12.1.2. Therapeutic Radiopharmaceuticals
12.1.2.1. Beta Emitters
12.1.2.2. Alpha emitters
12.1.2.3. Brachytherapy
12.1.2.4. Others
12.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Oncology
12.2.2. Neurological disorders
12.2.3. Cardiovascular diseases
12.2.4. Thyroid
12.2.5. Others
12.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Oral
12.3.2. Inhalation
12.3.3. Parenteral
12.4. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Hospitals
12.4.2. Clinics
12.4.3. Diagnostic Centers
12.4.4. Research Institutes
12.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. ASEAN
12.5.5. Australia & New Zealand
12.5.6. Rest of Asia-Pacific
12.6. Asia-Pacific Radiopharmaceuticals (Nuclear Medicine) Market - Opportunity Analysis Index, By Product Type, By Application, By Route of Administration, By End-User,and Country, 2017 – 2023
12.7. Europe Radiopharmaceuticals (Nuclear Medicine) Market Dynamics – Trends
13. LATIN AMERICA RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Diagnostic Radiopharmaceuticals
13.1.1.1. SPECT Radiopharmaceuticals
13.1.1.2. PET Radiopharmaceuticals
13.1.2. Therapeutic Radiopharmaceuticals
13.1.2.1. Beta Emitters
13.1.2.2. Alpha emitters
13.1.2.3. Brachytherapy
13.1.2.4. Others
13.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Oncology
13.2.2. Neurological disorders
13.2.3. Cardiovascular diseases
13.2.4. Thyroid
13.2.5. Others
13.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Oral
13.3.2. Inhalation
13.3.3. Parenteral
13.4. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.4.1. Hospitals
13.4.2. Clinics
13.4.3. Diagnostic Centers
13.4.4. Research Institutes
13.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Argentina
13.5.4. Venezuela
13.5.5. Rest of Latin America
13.6. Latin America Radiopharmaceuticals (Nuclear Medicine) Market - Opportunity Analysis Index, By Product Type, By Application, By Route of Administration, By End-User, and Country, 2017 – 2023
13.7. Latin America Radiopharmaceuticals (Nuclear Medicine) Market Dynamics – Trends
14. MIDDLE EAST AND AFRICA RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
14.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.1. Diagnostic Radiopharmaceuticals
14.1.1.1. SPECT Radiopharmaceuticals
14.1.1.2. PET Radiopharmaceuticals
14.1.2. Therapeutic Radiopharmaceuticals
14.1.2.1. Beta Emitters
14.1.2.2. Alpha emitters
14.1.2.3. Brachytherapy
14.1.2.4. Others
14.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.2.1. Oncology
14.2.2. Neurological disorders
14.2.3. Cardiovascular diseases
14.2.4. Thyroid
14.2.5. Others
14.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.3.1. Oral
14.3.2. Inhalation
14.3.3. Parenteral
14.4. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.4.1. Hospitals
14.4.2. Clinics
14.4.3. Diagnostic Centers
14.4.4. Research Institutes
14.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.5.1. Gulf Cooperation Council (GCC) Countries
14.5.2. Israel
14.5.3. South Africa
14.5.4. Rest of MEA
14.6. MEA Radiopharmaceuticals (Nuclear Medicine) Market - Opportunity Analysis Index, By Product Type, By Application, By Route of Administration, By End-User, and Country, 2017 – 2023
14.7. MEA Radiopharmaceuticals (Nuclear Medicine) Market Dynamics – Trends
15. COMPETITION LANDSCAPE
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Disease Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
15.2.1. Advanced Accelerator Applications S.A. (France)
15.2.2. Bayer AG (Germany)
15.2.3. Bracco Imaging S.p.A (Italy)
15.2.4. Cardinal Health, Inc. (U.S.)
15.2.5. Eli Lilly and Co. (U.S.)
15.2.6. GE Healthcare (U.S.)
15.2.7. IBA Molecular Imaging (Belgium)
15.2.8. Jubilant Life Sciences Ltd (India)
15.2.9. Lantheus Medical Imaging, Inc. (U.S.)
15.2.10. Mallinckrodt plc (Ireland)
15.2.11. Navidea Biopharmaceutical (U.S.)
15.2.12. Nordion, Inc. (Canada)
15.2.13. Siemens Healthineers (Germany)
16. RESEARCH METHODOLOGY
17. KEY ASSUMPTIONS AND ACRONYMS
